Tell us about your journey since graduating from CCAS.
If you'd told me at graduation that I'd spend more than three decades in drug development, I'm not sure I'd have believed you. But I've never had a reason to look elsewhere. I fell in love with science early on, but what has kept me rooted here is the profound, quiet connection to the patients who benefit from these life-saving medicines.
I started in 1990 in data management—entry-level, unglamorous, and exactly the right place to roll up my sleeves and learn how clinical trials actually work. From there, my path took me to G.D. Searle. While I was there, the company made an incredible, unprecedented investment in my potential: they removed a Senior Director from her day job entirely and assigned her to be my leadership mentor for a full year. That extraordinary mentorship shaped the executive I would become, and she remains both my dearest mentor and best friend to this day. From Searle, I moved to Pharmacia, and eventually Pfizer, which is where I first discovered a passion for leading large-scale transformations. Tasked with consolidating Development Operations into a single set of standards across the company, I realized I loved tackling complex systems just as much as I loved raw science. This was a season of three rapid-succession acquisitions by other companies. It was intense, but it taught me how to be resilient, creative, and a steady anchor for my teams during times of immense change. The lessons I learned from navigating being 'acquired' became invaluable later in my career when I was the one leading due diligence and bringing new, promising assets into our portfolio.
Then came Amgen, where I spent seventeen wonderful years. I arrived leading Clinical Data Management and left as Vice President of Global Development Operations, a role where I was fortunate to lead roughly 1,500 employees and another 6,000-plus partner personnel across more than 60 countries. Together, we completely reimagined how trials were delivered—pioneering risk-based execution, decentralized approaches, and eventually applying machine learning to trial analytics. I am immensely proud of how that team rallied during the darkest days of the COVID-19 pandemic; against all odds, they fought to keep approximately 150 clinical trials running safely and continuously for patients who depended on them. Another absolute milestone of my life was the approval of LUMAKRAS: the fastest oncology program in the industry at the time from first-in-human to first approval. That's not a corporate statistic to me. That represents years taken off the grueling wait for patients who simply didn't have years to spare.
After Amgen, I spent time as an independent advisor to biotechs, investors, and founders, which was a genuinely fun way to look at the industry from the other side of the table. But I missed being on the front line for the build. This past April, I joined Parabilis Medicines in Cambridge as Senior Vice President of Global Development Operations. What drew me back into the heart of a company was the exceptional science, a deeply collaborative culture, and the brilliant team I get to work alongside every day. It has been an exhilarating ride -- the company went public earlier this year as the most successful biotech launch in history. Standing with my colleagues at Times Square and sharing the absolute, indescribable rush of ringing the Nasdaq Closing Bell is a memory I will carry with me forever. Seeing our company name illuminated in lights wasn't just a corporate victory; it was a deeply emotional validation of the immense work our team has poured into these programs. Today, we are in a phase of rapid, thoughtful acceleration, working to double the size of our team while concurrently advancing multiple oncology indications in our development pipeline.
Across my career, I've been a part of bringing more than 130 medicines forward globally. That's the only number that truly matters to me. It represents lives lengthened, quality of life restored, and, most importantly, more birthdays, holidays, and memories for patients with their families. I know family members, close friends, and colleagues who are alive today because of medicines I’ve worked on. Hearing directly from those families brings a joy that is hard to put into words. Looking back, there isn’t another career on earth that could have given me this much purpose.
What inspired you to pursue your current career path?
As an undergraduate, I took a job working in the Emergency Room registration area at the GW Medical Center to help make ends meet. That job completely changed the trajectory of my life. It put me directly in the path of an active clinical trial, and I found myself watching, fascinated, as the study team approached patients and explained what participating would mean. At the time, I was finishing my biology degree, checking boxes to apply to medical school, and honestly feeling quite uncertain about what I wanted for my future. Seeing that trial up close opened a door to a world I didn't even know existed.
I started applying concurrently to MPH programs. The more I learned about drug development, the clearer my true calling became. This crystallized beautifully when I began working with the National Institute of Allergy and Infectious Diseases (NIAID) through Technical Resources Inc. Having the immense opportunity of directly supporting pivotal work on anti-retroviral treatments for AIDS showed me the tangible, global impact of clinical research. I made the terrifying decision to defer my medical school admission to pursue the MPH, fully intending to go back for the MD later.
I never looked back. I realized that while a doctor can change lives one exam room at a time, I could potentially reach millions of patients at scale by helping bring new medicines forward. Nearly 35 years later, that exact same mission is what gets me out of bed with a smile every morning.
How did your experience at CCAS shape you personally or professionally?
First, it cemented my lifelong love of science. I've never been someone who curls up with a fiction novel on a weekend—but I will happily read scientific journals and oncology research papers for hours. CCAS left no doubt in my mind that I belonged in the scientific community.
Second, and just as vital, was the liberal arts foundation. GW insisted on real exposure across the humanities, social sciences, and arts alongside our grueling lab hours. That combination was magic. It taught me how to think critically, see the human stories behind the data, and communicate clearly—whether writing a paper, speaking to thousands, or in a high-stakes boardroom.
Drug development isn't just one clinical job; it's a matrix of science, human behavior, business, and finance. The sheer breadth of my CCAS and MPH education is exactly what gave me the agility to navigate all of those worlds seamlessly throughout my career.
Were there any classes, professors, or experiences at GW that had a lasting impact on you?
I can't single out just one professor, and I mean that as the highest compliment to the faculty. From genetics and chemistry to sociology and psychology, every single teacher challenged the way I thought about the world. The courses and professors were demanding, and I absolutely loved them for it.
But the experience that shaped me most was simply growing up in Washington, D.C. The campus sits right in the middle of history, movement, and opportunity. If I have one regret, it's that I was in such a rush that I didn't slow down to appreciate the city enough back then. Remarkably, life gave me a beautiful do-over: my daughter earned her undergraduate degree at GW and is about to finish her Master's in Public Policy there. Walking those same Foggy Bottom streets with her, seeing the city properly through her eyes, and sharing that GW bond has been an absolute gift.
And, of course, I have to mention Thurston Hall. I arrived freshman year knowing absolutely no one and left with a family of friends for life. Just last year, I reconnected with one of my closest freshman roommates out in Los Angeles. We sat down, and within thirty seconds, it was as if no time had passed at all. That is the magic of GW that you'll never find in a course catalog.
In what ways do you stay connected to GW or the CCAS community?
Over the past decade, I've made a very intentional effort to give back to the place that gave me my start, and it has become one of the most fulfilling parts of my life.I've served on the Dean's Council for Arts & Sciences for eight years and currently serve as Vice Chair. Working alongside Dean Wahlbeck and the sub-committees has been a genuine honor, allowing me to help guide the future of the college that shaped me.
I also host Coffee Chats and mentoring sessions with students, which I always tell people are entirely bi-directional. I get to share my passion for drug development—a field many students don't even realize is a career option—and in return, I get energized by how this next generation thinks, what they care about, and what they want from the world.
Finally, I am an active donor. Knowing that my support might allow a student to breathe a little easier financially, so they can truly immerse themselves in the joy of the GW experience rather than stressing over a tuition balance, is a privilege I am always grateful for.
What advice would you give to current CCAS students or recent graduates?
Slow down. Take a breath.
I was in such a hurry to jump-start my 'career,' I pushed through and finished my degree in just three years. Looking back, that rush didn't buy me anything extra in the long run, but it absolutely cost me some of the social, messy, beautiful moments of being an undergraduate. Those years shape your soul more than your resume. Protect them. Take your time.
The second thing I'd tell you is to embrace the fact that your path will not be a straight line—and thank goodness for that. I deferred medical school with a rigid plan to return, only to stumble into a lifelong passion I didn't even know existed. Trust the detour. Stay open to the doors you weren't looking for, because they often lead to the most extraordinary places.
What is something people might be surprised to learn about you?
Looking at my career, people see someone who is fiercely 'all-in'—whether navigating massive acquisitions, keeping 150 clinical trials running through a pandemic, or scaling a team to launch an IPO. I think the surprise for many is that I don’t leave that intense energy at the office door. I am just as radically 'all-in' when it comes to my family.
The same drive that makes me fight for years off a patient’s wait time is what makes me fiercely protective of my time with my husband and children. I don't believe in just 'slowing down' to find balance; I believe in being deeply, passionately present wherever I am. If you see me at work, you're getting 100% of my focus. But if I am walking the streets of D.C. with my daughter celebrating her Master’s degree or catching up with lifelong friends, they get 100% of my heart. My family isn't what I do after work—they are the entire reason the work matters.